Literature DB >> 22670181

The efficacy of EBER in situ hybridization (ISH) stain in PTLD (malignant diffuse large B-cell lymphoma) about 4 years after ABO-incompatible kidney transplantation: a case report.

Kazuhiro Nose1, Takashi Oki, Eri Banno, Koichi Sugimoto, Tsukasa Nishioka, Ken Ochiai, Syunji Maekura.   

Abstract

Post-transplant lymphoproliferative disease (PTLD) is a well-known late complication of organ transplantation which incidence has increased after the introduction of more powerful immunosuppressive agents. A 58-year-old man performed ABO-incompatible living kidney transplantation in June, 2008. At 3 years and 9 months after the transplantation, the patient complained of general fatigue and dyspnea and was hospitalized with renal dysfunction. The clinical data in hospital showed acute rejection, but soluble IL-II exceeded 21700U/ml, and HE staining kidney graft showed a massive infiltration of atypical lymphocytes. Atypical lymphocytes were positive for L-26 and negative for CD3 immunochemical stein, and the EBER in situ hybridization stain for EBV was negative in renal graft. We diagnosed diffuse large B-cell lymphoma in the kidney graft. However, he died due to multiple organ failure (MOF). We described a fatal case of diffuse large B-cell lymphoma without EBV infection occurring 3 years 9 months after ABO-incompatible kidney transplantation. Unfortunately, post-mortem autopsy using EBER-ISH stain does not show whether EB virus infection was a cause.

Entities:  

Keywords:  ABO-incompatible living kidney transplantation; EBER in situ hybridization stain; PTLD

Mesh:

Substances:

Year:  2012        PMID: 22670181      PMCID: PMC3365825     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  7 in total

1.  Posttransplant lymphoproliferative disorder following kidney transplant.

Authors:  Alicia K Morgans; Ran Reshef; Donald E Tsai
Journal:  Am J Kidney Dis       Date:  2009-12-05       Impact factor: 8.860

Review 2.  Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options.

Authors:  Gyula Végso; Melinda Hajdu; Anna Sebestyén
Journal:  Pathol Oncol Res       Date:  2010-12-31       Impact factor: 3.201

3.  Risk factors for malignancy in Japanese renal transplant recipients.

Authors:  Tetsuya Imao; Naotsugu Ichimaru; Shiro Takahara; Yukito Kokado; Masayoshi Okumi; Ryoichi Imamura; Yukiomi Namba; Yoshitaka Isaka; Norio Nonomura; Akihiko Okuyama
Journal:  Cancer       Date:  2007-05-15       Impact factor: 6.860

4.  Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response.

Authors:  J Yang; Q Tao; I W Flinn; P G Murray; L E Post; H Ma; S Piantadosi; M A Caligiuri; R F Ambinder
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

5.  Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma.

Authors:  Margaret L Gulley; Sally L Glaser; Fiona E Craig; Michael Borowitz; Risa B Mann; Sarah J Shema; Richard F Ambinder
Journal:  Am J Clin Pathol       Date:  2002-02       Impact factor: 2.493

6.  Post-transplant lymphoproliferative disorder following renal transplantation: a single-center experience over 40 years.

Authors:  Toyofumi Abe; Naotsugu Ichimaru; Yukito Kokado; Tetsuo Maeda; Yoichi Kakuta; Masayoshi Okumi; Ryoichi Imamura; Norio Nonomura; Yoshitaka Isaka; Shiro Takahara; Akihiko Okuyama
Journal:  Int J Urol       Date:  2009-12-09       Impact factor: 3.369

Review 7.  The management of posttransplant lymphoproliferative disorder.

Authors:  Noelle V Frey; Donald E Tsai
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

  7 in total
  2 in total

Review 1.  Blood disorders typically associated with renal transplantation.

Authors:  Yu Yang; Bo Yu; Yun Chen
Journal:  Front Cell Dev Biol       Date:  2015-03-19

2.  Long noncoding RNA ZNF667-AS1 reduces tumor invasion and metastasis in cervical cancer by counteracting microRNA-93-3p-dependent PEG3 downregulation.

Authors:  Yong-Jie Li; Zhe Yang; Yi-Ying Wang; Yue Wang
Journal:  Mol Oncol       Date:  2019-10-17       Impact factor: 6.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.